Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Ltd. has released an analysis of its holdings, revealing that 157 holders collectively own 624,999,999 units, representing 100% of the company’s shares. The largest shareholder, Deborah Anne Coleman, holds 12.8% of the total securities. This distribution of holdings reflects the company’s shareholder structure and could influence future strategic decisions and investor relations.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates within the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company is known for its work in cell therapy, particularly in the field of chimeric antigen receptor (CAR) T-cell therapies, which are designed to harness the immune system to fight cancer.
Technical Sentiment Signal: Buy
Current Market Cap: A$11.34M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.